MedTrace Logo

Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects.

NCT04615962 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2020-11-04

No results posted yet for this study

Summary

The investigators aimed to understand better the efficacy in a randomized, double-blind, intraindividual design trial in 66 participants with AD treated with SNG100, and 2 different strengths of topical steroids hydrocortisone and the medium potent mometasone furoate cream.

Conditions

Interventions

DRUG

Hydrocortisone Acetate 1% Cream

Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.

DRUG

Mometasone Furoate

Mometasone is a medium-strength corticosteroid.

DRUG

SNG100

A combination of low potency steroid and skin barrier repair agent

Sponsors & Collaborators

  • Seanergy Dermatology Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuval Ramot, Prof. · Seanergy Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-01-31
Completion
2022-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04615962 on ClinicalTrials.gov